The Thesis
Exelixis is a cancer medicine company that builds and sells targeted therapies to treat various forms of advanced tumors. The company generated $2.17 billion in revenue during 2025, representing roughly 18% growth over the two year period prior. Reaching a 35% net margin and consistent GAAP profitability marks the structural shift where the business has transitioned from a risky research laboratory into a self-sustaining cash generator.
The bet here comes down to four specific things.
We see Exelixis as a multi-year compounder, driven by the steady cash flow of its lead drug and the potential of its new pipeline. The case for owning this only gets stronger if the company can prove it can dominate the colorectal cancer market with its new combination treatments. If the new drug launch fails or the lead drug loses market share to competitors like Merck, the thesis breaks. For long-term investors, this is a clean way to own a highly profitable oncology business.
Numbers at a Glance
What does it do?
Exelixis is a mature business that earns money by selling specialized cancer drugs and collecting royalties from partners who sell those drugs internationally. The company focuses on "small molecule" inhibitors, which are pills designed to block the specific proteins that help cancer cells grow and spread. When a doctor prescribes their lead drug, Cabometyx, the company earns revenue directly from the sale. They also receive a cut of every sale made by partners like Ipsen and Takeda in markets outside the United States.
Where does revenue come from?
The vast majority of revenue comes from U.S. sales of the Cabozantinib drug franchise. Net product sales accounted for $555 million of the $610.8 million in total revenue during the most recent quarter. Collaboration revenue, which is primarily royalties and milestone payments from international partners, provided the remaining $55.8 million.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Exelixis serves oncology clinics and hospitals that treat patients with advanced kidney, liver, and thyroid cancers. While the company does not disclose the total number of patients, its lead product, Cabometyx, generated $552.8 million in U.S. revenue last quarter alone. The company also manages high-level partnerships with global pharmaceutical giants who license their technology for foreign markets. These partners include Ipsen Pharma, which generated royalty revenue of $45.9 million for Exelixis in the most recent three month period.
What gives it staying power?
The company’s staying power comes from a massive wall of patent protection and clinical trial data that makes its drugs the standard of care for specific cancers. Doctors are hesitant to switch a patient to a different drug once a treatment is working. This creates high switching costs and predictable revenue.
Where is it headed?
The company is betting its future on Zanzalintinib, a next-generation version of its current blockbuster drug. Management is currently running several large "pivotal" clinical trials to prove this new drug can treat more types of cancer with fewer side effects. If these trials succeed, it allows Exelixis to extend its dominance in the cancer market well into the next decade.
Revenue growth remains steady as the company extracts more value from its lead drug while preparing for its next launch. Total revenue grew to $610.8 million in the first quarter of 2026, a 10% increase over the same period the prior year. This steady pace proves the core business is not yet slowing down.
Cash generation is exceptional because the company has finished the most expensive early stages of its primary drug development. Free cash flow hit $840 million in 2026, allowing the company to fund all new research while still having enough left over for massive buybacks. This high cash quality means the business can grow without needing to borrow money.
The balance sheet is a fortress with a tiny debt-to-equity ratio of 0.09x and a massive cash pile. Management is using this strength to retire shares rather than hoarding cash. This financial flexibility allows them to weather any delays in the FDA approval process for new drugs.
Exelixis is a financially dominant biotech with elite profit margins and a massive cash surplus that protects shareholders from pipeline risk.
Net margins have reached a staggering 35.1%, which is far above the average for the broader pharmaceutical industry. This efficiency allows the company to generate nearly a dollar of profit for every three dollars in sales. It also gives them the capital to run seven different pivotal drug trials at once without hurting the bottom line.
Research and development costs are the largest variable that could eat into future profits. While spending dropped to $199.9 million last quarter, a sudden surge in trial costs for Zanzalintinib could compress margins. Management must balance the need for new drugs with the discipline required to keep the stock buyback program on track.
The global oncology market is roughly $200 billion today, growing at 11% annually, and is on track to exceed $340 billion by 2029. Pricing power is structural in this industry because insurers and Medicare are willing to pay a premium for drugs that measurably extend human life. Exelixis stands as a dominant niche leader in the kidney and liver cancer markets. This provides a deep well of cash that can be used to attack larger markets like colorectal and prostate cancer in the coming years.
The competitive dynamic in oncology is intensely scientific but rationally structured around clinical trial data. Barriers to entry are massive because developing a new drug costs billions and takes over a decade. This protects established winners who have already cleared the regulatory hurdles.
Merck(MRK) is the most dangerous threat because its drug, Keytruda, is the foundation of many combination treatments. Bristol-Myers Squibb(BMY) also competes directly for kidney cancer patients with its own immune-system therapies. The most significant threat comes from Merck’s attempts to bundle its own internal drugs together to exclude Exelixis from the treatment plan.
Exelixis is holding ground and actually expanding its reach through new combination studies. The company reported a 10% increase in product sales volume last quarter, proving it is still winning new patients.
The primary source of protection is intellectual property backed by a massive library of proprietary clinical data. Doctors rely on years of evidence from STELLAR and COSMIC trials to justify prescribing these drugs over cheaper alternatives. This creates a switching cost moat where the risk of a patient’s cancer returning far outweighs the benefit of trying a new, unproven medicine.
The financial metrics confirm this advantage is real and durable. A 35% ROIC and 96.4% gross margin are almost impossible to achieve without a structural edge that prevents competitors from competing on price. These are the numbers of a business that controls its market rather than one that reacts to it.
The moat is strengthening as the company builds a second pillar with Zanzalintinib.
Consistent revenue beats and 42% YoY EPS growth in the latest quarter.
Authorized a new $750 million share repurchase program in May 2026.
CEO Morrissey oversees a multi-billion dollar buyback program while maintaining high margins.
Capital Allocation Track Record
Michael Morrissey has led Exelixis through a successful transition from a research-focused firm to a high-margin commercial power. The decision to aggressively repurchase $1.5 billion in stock over two years shows a rare level of discipline for a biotech company. Management consistently hits their clinical trial milestones and has maintained elite profitability even while funding seven major new studies.
© 2026 ClearThesis.ai · Report generated on May 27, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.